The FDA first approved of chimeric antigen receptor (CAR) T cell therapy in 2017, and Penn Medicine has since been dedicated to finding further applications to the treatment.
The New York Post recently published an article discussing future applications of mRNA, including vaccinations against tuberculosis, malaria, high cholesterol, HIV, and more.
4D Molecular Therapeutics (4DMT) Acquires Rights to Penn Medicine Invented Technology from Aevitas Therapeutics
Penn spinout Aevitas Therapeutics recently executed an asset purchase agreement with California-based biotechnology company 4D Molecular Therapeutics (4DMT).
Teva Pharmaceuticals and MedinCell recently received approval from the U.S. Food and Drug Administration (FDA) for UZEDY™ (risperidone).
The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging co
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
This technology is an intracerebral drug delivery system that consists of three flexible, retractable microcannulas housed within a single central catheter.
Penn Medicine, CHOP receive $25M anonymous gift to accelerate research in rare genetic brain disorders
The donation will establish the Center for Epilepsy and Neurodevelopmental Disorders, which will initially focus on developing therapies for disorders related to genetic mutations that are linked to a
Penn Scientists New Research Shows That a CAR-T gel Treatment May Be Able to Kill Residual Cancer Cells Left Over from Surgery
In the study, Penn scientists added CAR-T cells to a gel designed to prevent bleeding after surgery and applied it to the surgical wounds of mice after they had hard-to-treat tumors resected.